- $593.15m
- $541.47m
- $43.47m
- 38
- 13
- 96
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.63 | ||
| PEG Ratio (f) | 0.1 | ||
| EPS Growth (f) | 10,810.97% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.01 | ||
| Price to Tang. Book | 7.16 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.64 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.3% | ||
| Return on Equity | -23.17% | ||
| Operating Margin | -51.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.24 | 0.19 | 0.07 | n/a | 43.47 | 131.12 | 196.84 | 173.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +121.88 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Directors
- Myron Kaplan NEC (73)
- Matthew David CEO (43)
- Phoebe Mounts EVP (71)
- Elizabeth Masson Hurlburt EVP (42)
- Thomas Nusbickel OTH
- Paulo Costa IND (71)
- Janet Dillione IND (62)
- Gregory Duncan IND (56)
- Alan Dunton IND (67)
- Steven Lefkowitz IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 28th, 2006
- Public Since
- March 25th, 2010
- No. of Shareholders
- 62
- No. of Employees
- 64
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 65,181,771
- Address
- 300 Connell Drive, Suite 4200, BERKELEY HEIGHTS, 07922
- Web
- https://cormedix.com/
- Phone
- +1 9085179500
- Contact
- Dan Ferry
- Auditors
- Marcum LLP
Upcoming Events for CRMD
Q2 2025 CorMedix Inc Earnings Release
Similar to CRMD
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the CorMedix share price?
As of Today at 20:04 UTC, shares in CorMedix are trading at $9.10. This share price information is delayed by 15 minutes.
How has the CorMedix share price performed this year?
Shares in CorMedix last closed at $9.10 and the price had moved by +75.34% over the past 365 days. In terms of relative price strength the CorMedix share price has outperformed the S&P500 Index by +61.84% over the past year.
What are the analyst and broker recommendations for CorMedix?
The overall consensus recommendation for CorMedix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the CorMedix dividend yield?
CorMedix does not currently pay a dividend.
Does CorMedix pay a dividend?
CorMedix does not currently pay a dividend.
When does CorMedix next pay dividends?
CorMedix does not currently pay a dividend.
How do I buy CorMedix shares?
To buy shares in CorMedix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CorMedix?
As of the previous close price of $9.10, shares in CorMedix had a market capitalisation of $593.15m.
Where are CorMedix shares listed?
Here are the trading details for CorMedix:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CRMD
What kind of share is CorMedix?
Based on an overall assessment of its quality, value and momentum CorMedix is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CorMedix share price forecast for 2025?
The analyst consensus target price for shares in CorMedix is $15.50. That is 70.33% above the last closing price of $9.10.
Analysts covering CorMedix currently have a consensus Earnings Per Share (EPS) forecast of $0.68 for the next financial year.
Find out moreWhat is the trend in the CorMedix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CorMedix. Over the past six months, its share price has underperformed the S&P500 Index by -26.45%.
As of the last closing price of $9.10, shares in CorMedix were trading +6.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CorMedix PE Ratio?
The CorMedix PE ratio based on its reported earnings over the past 12 months is 9.63. The shares last closed at $9.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CorMedix?
CorMedix's management team is headed by:
- Myron Kaplan - NEC
- Matthew David - CEO
- Phoebe Mounts - EVP
- Elizabeth Masson Hurlburt - EVP
- Thomas Nusbickel - OTH
- Paulo Costa - IND
- Janet Dillione - IND
- Gregory Duncan - IND
- Alan Dunton - IND
- Steven Lefkowitz - IND